Drugs / F-18 PSMA 1007
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03768349 | Jan 2019 → Jul 2021 | prostate cancer | Mayo Clinic | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04102553 | Mar 2019 → Oct 2020 | prostate cancer | ABX advanced biochemical compounds GmbH | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | F-18-PSMA-1007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04102553 ↗ |
| Modality | Diagnostic / imaging agent | “F-18 PSMA 1007 PET/CT for detection of tumor location” NCT03768349 ↗ |